Actinogen Medical Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATGGF research report →
About the company
Actinogen Medical Limited is an Australian biotechnology firm specializing in the creation of treatments for neurological and neuropsychiatric conditions linked to abnormal brain cortisol levels. Their primary therapeutic candidate, Xanamem, functions as an inhibitor of the 11ß-HSD1 enzyme. Currently in Phase 2 clinical trials, Xanamem has shown the ability to engage its intended target within the central nervous system.
- CEO
- Steven G. Gourlay
- IPO
- 2018
- Employees
- 6
- HQ
- Sydney, NSW, AU
Price Chart
- Market Cap
- $2.97M
- P/E
- -6.49
- P/S
- 24.71
- P/B
- 13.90
- EV/EBITDA
- -6.51
- Div Yield
- 0.00%
- Gross Margin
- 96.16%
- Op Margin
- -365.31%
- Net Margin
- -326.26%
- ROE
- -134.14%
- ROIC
- -146.52%
- Revenue
- $5.49M · -44.73%
- Net Income
- $-14,732,263 · -12.94%
- EPS
- $-0.00 · 18.33%
- Op Income
- $-14,932,044
- FCF YoY
- 55.22%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.03
- Beta
- 0.82
- Avg Volume
- 16
Get TickerSpark's AI analysis on ATGGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ATGGF coverage
Recent articles, reports, and earnings notes.
No research on ATGGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATGGF report →Similar companies
Peers in the same neighborhood.